KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Common Equity: 2011-2024

Historic Common Equity for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to $59.1 million.

  • Travere Therapeutics' Common Equity rose 341.56% to $73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $73.6 million, marking a year-over-year increase of 341.56%. This contributed to the annual value of $59.1 million for FY2024, which is 70.58% down from last year.
  • As of FY2024, Travere Therapeutics' Common Equity stood at $59.1 million, which was down 70.58% from $200.8 million recorded in FY2023.
  • Travere Therapeutics' 5-year Common Equity high stood at $302.1 million for FY2021, and its period low was $42.9 million during FY2022.
  • In the last 3 years, Travere Therapeutics' Common Equity had a median value of $59.1 million in 2024 and averaged $100.9 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 85.82% in 2022, then spiked by 368.62% in 2023.
  • Yearly analysis of 5 years shows Travere Therapeutics' Common Equity stood at $211.2 million in 2020, then soared by 43.04% to $302.1 million in 2021, then plummeted by 85.82% to $42.9 million in 2022, then skyrocketed by 368.62% to $200.8 million in 2023, then slumped by 70.58% to $59.1 million in 2024.